<u>Supplement</u>

Unique Features of Genome Sequencing for Rare Disease Diagnosis

Contents:

Methods	2
Sequencing	2
Analysis	3
Variant classification	5
References	5
Table S1 Standard searches used by the Broad team for ES/GS analysis	9
Figure S1 Classification of variants	10
Table S2. Diagnoses	11
Table S3. Candidates	12
Table S4. Diagnostic yield by imputed ancestry	15

Sequencing Methods

Genome sequencing (GS) was performed by the Genomics Platform at the Broad Institute of MIT and Harvard. PCR-free preparation of sample DNA (350 ng input at >2 ng/ul) is accomplished using Illumina HiSeq X Ten v2 chemistry. Libraries are sequenced to a mean target coverage of 30x. GS data was processed through a pipeline based on Picard, using base quality score recalibration and local realignment at known indels. The BWA aligner was used for mapping reads to the human genome build 38 (GRCh38). Single nucleotide variants and insertions/deletions (indels) were jointly called across all samples using Genome Analysis Toolkit (GATK) HaplotypeCaller package version 4.0. Default filters were applied to SNV and indel calls using the GATK Variant Quality Score Recalibration (VQSR) approach. Annotation was performed using Variant Effect Predictor (VEP). GATK-SV¹ was used to detect structural variants (SVs), which were annotated with the GATK SVAnnotate tool. Mitochondrial DNA (mtDNA) single nucleotide and small indel variants were called from GS data using the gnomAD-mitochondria pipeline² and large mtDNA deletions were called by MitoSAlt³. ExpansionHunter v5 was used to genotype known disease-associated tandem repeat expansions (TREs).⁴ Lastly, the variant call set was uploaded to seqr for collaborative analysis between the CMG and investigator or for analysis by the RGP team.⁵

ES was performed prior to GS for many of these cases through a variety of clinical diagnostic laboratories or by the Genomics Platform at the Broad Institute. For these cases, libraries from DNA samples (>250 ng of DNA, at >2 ng/ul) were created with an Illumina Nextera exome capture (38 Mb target) and sequenced (150 bp paired reads) to cover >80% of targets at 20x and a mean target coverage of 80x until January 2019 and thereafter using a Twist exome capture (~38 Mb target) and sequenced (150 bp reads) to cover > 90% of targets at 20x and a mean target coverage of 80x. Sample identity quality assurance checks were performed on each sample. The ES data was de-multiplexed and each sample's sequence data were aggregated into a single Picard BAM file. ES data was subsequently processed similar to GS data as previously described.

Analysis

The Broad CMG analysis team has developed four standard searches that are applied for each family (Table S1). We prioritize variants for further study that have high pathogenicity scores using common *in silico* predictors (e.g. REVEL⁶, CADD⁷, SIFT⁸, PolyPhen-2⁹,

MutationTaster¹⁰, MPC¹¹), occur at highly conserved residues as determined by manual review on the UCSC genome browser and evaluating the Genomic Evolutionary Rate Profiling (GERP) score¹². We visually inspect the read data using the Integrated Genomics Viewer (IGV) for our candidate variants to ensure they are not sequencing artifacts. Top candidate variants are typically confirmed by an orthogonal method such as Sanger sequencing.

To detect SVs, we initially utilized multiple SV-calling tools including Manta¹³, DELLY¹⁴, and Smoove (https://github.com/brentp/smoove), and more recently applied GATK-SV: an ensemble SV detection tool that discovers, genotypes, and resolves the diverse classes of SVs that can be captured from GS data, including balanced and unbalanced CNVs, inversions, insertions, translocations, and a spectrum of complex SVs. Briefly, GATK-SV maximizes sensitivity by harmonizing five algorithms, then adjudicating and re-genotyping SVs from raw read evidence¹. GATK-SV considers all SV evidence available from GS, including discordant paired-end (PE) or split reads (SR) crossing a breakpoint, and normalized read-depth (RD) or B-allele frequencies. Each CRAM file is processed with five algorithms, which currently include two PE/SR algorithms (Manta¹³, Wham¹⁵), two RD algorithms (cnMOPS¹⁶ and GATK-gCNV¹⁷), and a mobile element algorithm, MELT¹⁸. GATK-SV is publicly available on GitHub (https://github.com/broadinstitute/gatk-sv). For CNV analysis, we also apply germline Copy Number Variant caller (gCNV), a coverage-based CNV detection method that normalizes coverage across the exome by adjusting for systematic bias and uses a probabilistic framework to infer copy number from the normalized coverage. We manually evaluate the CNV data, filtering out low-quality calls and inherited variants (based on family history) and focus our analysis on CNVs overlapping protein-coding genes. For cases with a strong phenotype pointing to a particular gene or genes as the likely candidate, we may also manually search for SVs by visually-inspecting the reads across the gene in question (using the Integrated Genomics Viewer¹⁹).

To evaluate for tandem repeat expansions (TREs), we run ExpansionHunter v5²⁰ on GS samples to genotype 60 known disease-associated repeat loci. The locus specifications we use are publicly available on github (https://github.com/broadinstitute/str-analysis) and represent the same list of loci for which population frequencies are available in the gnomAD browser (https://gnomad.broadinstitute.org/short-tandem-repeats?dataset=gnomad_r3). We also run REViewer²¹ to generate read visualizations. Then, to identify candidate pathogenic expansions, we evaluate individuals with the most-expanded genotypes for each locus, comparing them to the pathogenic threshold and population frequencies for this locus in gnomAD. We also evaluate genotype qualities based on reviewing read visualizations.

To evaluate mtDNA SNVs and indels, we run the mitochondria mode of Mutect2 followed by the gnomAD-mitochondria pipeline². Then, to identify candidate variants, we search for "confirmed" variants listed in MITOMAP²² and P/LP variants listed in ClinVar. We finally review all mtDNA variants of uncertain significance (VUS) reported in ClinVar and/or with

"reported" status in MITOMAP, in addition to unreported variants with pathogenic *in silico* prediction based on mtDNA-specifications of the ACMG/AMP guidelines (APOGEE ≥ 0.5 for missense variants; MitoTIP > 12.66 plus HmtVar ≥ 0.35 for tRNA variants), that are absent at high heteroplasmy level (\geq 80%) or homoplasmy ($\geq 95\%$) in reference databases (gnomAD v3 and HelixMTdb).

Variant classification

In order to systematically assess the pathogenicity of the structural variants that we identified, the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen) standards for classification and reporting of constitutional copy-number variants were applied²³. Variants in novel gene-disease relationships are classified as VUS until the gene-disease relationship has at least moderate evidence supporting it. CNV associated with disorders that follow an autosomal recessive or X-linked mode of inheritance are not addressed in these standards and required additional consideration; the classification criteria were modified to optimally capture evidence for pathogenicity for the range of variants that we identified. Relative proportions of VUS to pathogenic/likely pathogenic variants are presented in Figure S1.

References

- Collins RL, Brand H, Karczewski KJ, et al. A structural variation reference for medical and population genetics. Nature 2020;581(7809):444-451.
- Laricchia KM, Lake NJ, Watts NA, et al. Mitochondrial DNA variation across 56,434 individuals in gnomAD. Genome Res 2022;32(3):569-582.
- Basu S, Xie X, Uhler JP, et al. Accurate mapping of mitochondrial DNA deletions and duplications using deep sequencing. PLoS Genet 2020;16(12):e1009242.

- Dolzhenko E, Deshpande V, Schlesinger F, et al. ExpansionHunter: a sequence-graphbased tool to analyze variation in short tandem repeat regions. Bioinformatics 2019;35(22):4754-4756.
- Pais LS, Snow H, Weisburd B, et al. seqr: A web-based analysis and collaboration tool for rare disease genomics. Hum Mutat 2022;43(6):698-707.
- Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet 2016;99(4):877-885.
- Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014;46(3):310-5.
- 8. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acid Res 2012;40:452.
- 9. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7(4):248-9.
- Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nature methods 2014;11(4):361-362.
- Kaitlin E. Samocha, Jack A. Kosmicki, Konrad J. Karczewski, Anne H. O'Donnell-Luria, Emma Pierce-Hoffman, Daniel G. MacArthur, Benjamin M. Neale, Mark J. Daly. bioRxiv 148353; doi: <u>https://doi.org/10.1101/148353</u>.
- Huber CD, Kim BY, Lohmueller KE. Population genetic models of GERP scores suggest pervasive turnover of constrained sites across mammalian evolution. PLoS Genet 2020;16(5):e1008827.

- Chen X, Schulz-Trieglaff O, Shaw R, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 2016;32(8):1220-2.
- Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 2012;28(18):i333-i339.
- Kronenberg ZN, Osborne EJ, Cone KR, et al. Wham: Identifying Structural Variants of Biological Consequence. PLoS Comput Biol 2015;11(12):e1004572.
- Klambauer G, Schwarzbauer K, Mayr A, et al. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Res 2012;40(9):e69.
- 17. Fu JM, Satterstrom FK, Peng M, et al. Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. Nat Genet 2022;54(9):1320-1331.
- Gardner EJ, Lam VK, Harris DN, et al. The Mobile Element Locator Tool (MELT): population-scale mobile element discovery and biology. Genome Res 2017;27(11):1916-1929.
- Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): highperformance genomics data visualization and exploration. Brief Bioinform 2013;14(2):178-92.
- Dolzhenko E, van Vugt J, Shaw RJ, et al. Detection of long repeat expansions from PCRfree whole-genome sequence data. Genome Res 2017;27(11):1895-1903.
- 21. Dolzhenko E, Weisburd B, Ibanez K, et al. REViewer: haplotype-resolved visualization of read alignments in and around tandem repeats. Genome Med 2022;14(1):84.

- 22. Kogelnik AM, Lott MT, Brown MD, Navathe SB, Wallace DC. MITOMAP: a human mitochondrial genome database--1998 update. Nucleic Acids Res 1998;26(1):112-5.
- 23. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med 2020;22(2):245-257.
- 24. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020;581(7809):434-443.
- Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing from Primary Sequence with Deep Learning. Cell 2019;176(3):535-548.e24.

Search	Variant annotations	Variant frequency (Broad callset, gnomAD ²⁴ , gnomAD SV ¹)	Variant call quality	Annotation overrides (SpliceAI score ²⁵)
Dominant/ <i>de</i> <i>novo</i> restrictive	Coding variants, essential and extended splice site, LOF SVs	0.001 gnomAD 0.01 callset	Pass VQSR GQ 40 AB 20	ClinVar LP/P SpliceAI >0.2
Recessive restrictive	Coding variants, essential and extended splice site, LOF SVs	0.01 gnomAD 0.03 callset	Pass VQSR GQ 40 AB 20	ClinVar LP/P SpliceAI >0.2
Dominant/de novo permissive	Coding variants, synonymous, splice, 5/3'UTR, Non-coding exons, TFBS, regulatory region, LOF/intronic/UTR/promoter SVs	0.001 gnomAD 0.01 callset	GQ 40 AB 10	ClinVar LP/P/VUS SpliceAI >0.1
Recessive	Coding variants, synonymous, splice, 5/3'UTR, Non-coding exons, TFBS, regulatory region, LOF/intronic/UTR/promoter SVs	0.01 gnomAD 0.03 callset	GQ 40 AB 10	ClinVar LP/P/VUS SpliceAI >0.1

Table S1: Standard searches used by the Broad team for ES/GS analysis

Legend: LOF: Loss of function; VQSR: Variant Quality Score Recalibration; GQ: Genotype quality; AB: allele balance; LP/P: Likely pathogenic/pathogenic; UTR: Untranslated region; TFBS: transcription factor binding site; VUS: Variant of uncertain significance

Figure S1. Classification of variants. Pathogenicity of 284 variants in 218 families solved via GS, classified as per the ACMG/AMP/ClinGen standards.



Table S2. DiagnosesSee separate spreadsheet

ID	Gene
UWA_LAI963	ABCD3
HK115	ACSL5
SCO_PED096	ADGRE3
BON_B17-59	AFAPILI
SOU_FAM00008	AGMAT
HK103	ANOI
HK081	ANO2
RGP_696	ARFGEF3
CHU_05	ARHGAP6
RGP_245	BAZIB
RGP_12	BLOCISI
RGP_655	BOD1
CHU_23	C10orf71
RGP_572	CACNA2D3
RGP_658	CAMK1D
RGP_284	CAMK4
HK060	CBX8
HK017	CDK11B
RGP_735	CDK16
IK	CDK5RAP3
RGP_1374	CEP192
BEG_0761	CFAP46
RGP_868	CFAP54
CMG_Laing_Ravencroft_WGS	COL5A3
RGP_1333	DIPK2B
RGP_45	DNAH17
RGP_1149	EBF2
49	ELK1
UWA_LAI1646	EP400
RGP_726	ЕРНА6
RGP_54	ERICH3
RGP_1268	ETVI
827	FAM193A
RGP_1180	FBXO42
RGP_375	FGF7
HK085	FLYWCH1
RGP_1150	FRG2

Table S3. Candidates. Candidate novel disease genes identified in this cohort.

RGP_86	FRMPD3	
RGP_589	FURIN	
RGP_1129	GFPT1	
RGP_119	GRM4	
HK028	GTF2A1	
НК032	HAPLN2	
HK044	HEATRI	
HK075	HELZ	
RGP 673	HNRNPL	
VCGS FAM148	HOXC8	
RGP 1016	INTS6L	
CHU 04	ISLR2	
RGP 1479	KCNH8	
RGP 95	KDM4A	
RGP 1392	KDM8	
HK080	KIAA0408	
RGP 1526	KLHL13	
FAM39	LATS2	
RGP_1498	LBX1	
RGP_289	MACO1	
RGP_105	MARCH5	
RGP_20	MAU2	
HK104	MCRS1	
RGP_674	MRPL54	
RGP_1175	MYH1	
BON_B18-54	МҮО7В	
RGP_526	NCOR1	
RGP_1425	NCOR2	
RGP_495	NELL2	
RGP_314	OSBPL9, SYNRG	
RGP_1138	PACSIN3	
RGP_329	PKP4	
RGP_1193	PPP1R12C	
RGP_232	PRICKLE3, GNA13	
RGP_1504	PRPF4B	
VCGS_FAM52	PRPS2	
RGP 853	PTPRG	
RGP_53	RAB33A	
MAN_1601	RCOR2	

RGP_230	RHPN2
RGP_469	RIMS1
235	RPL37A
GI	SARNP
RGP_402	SCRIB
RGP_522	SCTR
НК035	SH3GL1
1024	SHCBP1
НК072	SMG6
RGP_1099	SMYD1
FAM61	SNED1
RGP_682	SRGAP2
RGP_731	SRRT
RGP_5	SSBP3
RGP_135	SSH1
RGP_918	SYNM
CHU_01	TBC1D22A
RGP_431	THAP12
RGP_951	THBS2
RGP_677	TLKI
RGP_123	TPPP
FAM29	TPR
VCGS_FAM147	TRABD2B
966	TTC28
RGP_452	TXLNG
RGP_1101	UNC13B
VCGS_FAM2	UNC5C
RGP_1125	VPS37D
FAM1	WWP1
RGP_504	ZBTB1
RGP_763	ZC3H11A

Ancestry Category	Total	Diagnosed
	(N, % of cohort)	(N, % of subgroup)
African/African	22 (3.0%)	5 (22%)
American		
Ashkenazi Jewish	33 (4.4%)	20 (61%)
East Asian	12 (1.6%)	2 (17%)
European	570 (76.6%)	170 (43%)
Latino/Admixed	27 (3.6%)	4 (15%)
American		
Middle Eastern	2 (0.3%)	1 (50%)
South Asian	13 (1.7%)	4 (31%)
Multiple/Unknown	65 (8.7%)	19 (29%)

Table S4. Diagnostic yield by imputed ancestry